SEC Form 4 · accession 0000899243-16-028032
Marker Therapeutics, Inc. · MRKR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Loiacono
Officer — Chief Financial Officer
Period of report
Aug 25, 2016
Accepted (ET)
Aug 25, 2016 · 9:03 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001094038
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.475 | Aug 25, 2016 | A | 650,000 | A | — | Aug 25, 2026 | Common Stock | 650,000 | 650,000 | D |
Explanation of responses
- F1Represents options awarded under the Company's 2014 Omnibus Stock Ownership Plan in connection with the execution of Mr. Loiacono's employment agreement with the Company. 75,008 options shall vest immediately and the remaining options shall vest in 36 equal monthly installments of 15,972 options on the last day of each of the 36 months following the grant date. The option exercise price is the closing price on August 24, 2016 the trading day immediately prior to the award date.